Teligent (NASDAQ:TLGT) received a $4.00 price target from equities researchers at Canaccord Genuity in a research report issued to clients and investors on Saturday. The firm currently has a “hold” rating on the stock. Canaccord Genuity’s price objective points to a potential upside of 4.71% from the company’s previous close.

A number of other analysts have also recently weighed in on the stock. Zacks Investment Research cut shares of Teligent from a “hold” rating to a “strong sell” rating in a research note on Saturday, November 11th. TheStreet cut shares of Teligent from a “c-” rating to a “d+” rating in a research note on Wednesday, November 1st. Deutsche Bank lowered their target price on shares of Teligent from $9.00 to $8.00 and set a “hold” rating on the stock in a research note on Monday, August 14th. Finally, Roth Capital set a $9.00 price objective on shares of Teligent and gave the stock a “buy” rating in a research note on Wednesday, August 23rd. Three analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $7.00.

Teligent (TLGT) opened at $3.82 on Friday. The company has a current ratio of 3.28, a quick ratio of 2.71 and a debt-to-equity ratio of 2.23. Teligent has a 52-week low of $2.82 and a 52-week high of $9.54.

Teligent (NASDAQ:TLGT) last announced its quarterly earnings data on Monday, November 6th. The company reported ($0.08) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.01) by ($0.07). The company had revenue of $13.65 million for the quarter, compared to analyst estimates of $19.12 million. Teligent had a negative net margin of 16.95% and a negative return on equity of 6.51%. The firm’s quarterly revenue was down 15.5% on a year-over-year basis. During the same period in the prior year, the company posted $0.01 EPS. analysts expect that Teligent will post -0.2 earnings per share for the current fiscal year.

A number of institutional investors have recently modified their holdings of TLGT. Barclays PLC grew its stake in shares of Teligent by 306.5% during the first quarter. Barclays PLC now owns 25,013 shares of the company’s stock valued at $100,000 after purchasing an additional 18,859 shares during the last quarter. Creative Planning grew its stake in shares of Teligent by 17.4% during the third quarter. Creative Planning now owns 13,500 shares of the company’s stock valued at $103,000 after purchasing an additional 2,000 shares during the last quarter. Parkwood LLC bought a new stake in shares of Teligent during the second quarter valued at approximately $112,000. Teza Capital Management LLC bought a new stake in shares of Teligent during the first quarter valued at approximately $116,000. Finally, A.R.T. Advisors LLC bought a new stake in shares of Teligent during the first quarter valued at approximately $119,000. 70.83% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: This article was originally published by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/12/10/teligent-tlgt-pt-set-at-4-00-by-canaccord-genuity.html.

Teligent Company Profile

Teligent, Inc is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.

Receive News & Ratings for Teligent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent Inc. and related companies with MarketBeat.com's FREE daily email newsletter.